/
We are a cellular and regenerative medicine company focused on advancing health longevity and redefining the standard of care for age-related disease using novel therapies derived from the post-partum human placenta. The objective of extending health longevity is to meaningfully reduce the duration and severity in which an individual experiences aging-related degenerative diseases and disorders…
The business is unprofitable at the operating level (-230.92% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 51.0% YoY. Margins deteriorated 160.2pp alongside, both lines moving the wrong way.
ROIC dropped from -65.01% to -307.40%, capital efficiency is deteriorating. Negative free cash flow of -$13M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$27M
▼ -51.0% YoY
Net Income (TTM)
-$92M
▼ -58.4% YoY
Op. Margin
-230.92%
▼ -160.2pp YoY
ROIC
-307.40%
▼ -242.4pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$13M
▼ -102.0% YoY
Op. Cash Flow (TTM)
-$13M
▼ -107.1% YoY
Net Debt
$55M
Cash & Equiv.
$6M
5Y CAGR: +13.2%
Continue Research